Content
Breadcrumbs
Should we be grateful or worried about the pace of COVID-19 vaccine development?
Part of the BTEC Fall 2020 Seminar Series
Friday, Sept. 25, 2020
10:40–11:30 a.m.
The BTEC fall seminar series kicks off Friday, Sept. 25 with an online presentation from 10:40–11:30 a.m. by Dr. Paul Evans of Velocity Clinical Research entitled “If clinical trials are normally so slow, should we be worried about the pace of COVID-19 vaccine development or just grateful?”
All NC State faculty, staff and students are invited to attend the Zoom session using the following link: go.ncsu.edu/btec_seminar
About the presenter
Paul Evans, PhD, has worked in the pharmaceutical industry for over 30 years. He is currently president and chief executive officer of Velocity Clinical Research. Velocity owns and operates investigator sites across multiple therapeutic areas in the United States.
Dr. Evans began his career establishing and managing research sites in the UK and was a founder of one of the first European SMOs. He pioneered innovative patient recruitment approaches as he built a site network with a reputation for outstanding delivery. This included the first phase III television advertising campaigns in the UK and some of the earliest Internet-based patient outreach programs at the turn of the century. Paul joined the CRO sector in 2005, building global site networks that partnered strategically rather than being selected tactically by the CRO, and continued to work on innovative patient recruitment campaigns across all continents. In two of the world’s largest CROs, he has led global functions that have included site intelligence, study start-up, feasibility, site contracting, patient recruitment and investigator payments. The experience Dr. Evans has had gives him unique insight into the challenges faced by the drug development industry.